The RPGR (retinitis pigmentosa GTPase regulator) gene has been shown to be mutated in 10-20% of patients with X-linked retinitis pigmentosa (XLRP), a severe form of inherited progressive retinal degeneration. A total of 29 different RPGR mutations have been identified in northern European and United States patients. We have performed mutation analysis of the RPGR gene in a cohort of 49 southern European males affected with XLRP. By multiplex SSCA and automatic direct sequencing of all 19 RPGR exons, seven different and novel mutations were identified in eight of the 49 families; these include three splice site mutations, two microdeletions, and two missense mutations. RNA analysis showed that the three splice site defects resulted in the generation of aberrant RPGR transcripts. Six of these mutations were detected in the conserved amino-terminal region of RPGR protein, containing tandem repeats homologous to the RCC1 protein, a guanine nucleotide-exchange factor for RanGTPase. Several exonic and intronic sequence variations were also detected. None of the RPGR mutations reported in other populations were identified in our series. Our results are consistent with the notions of heterogeneity and minority causation of XLRP by mutations in RPGR in Caucasian populations.
Introduction
X-linked retinitis pigmentosa (XLRP) is a severe retinal degeneration that typically causes night blindness, loss of peripheral vision within the first or second decades of life, legal blindness by 30 years of age, and often complete functional blindness by 40 or 50. [1] [2] [3] At least two loci on the X chromosome can mutate to cause retinitis pigmentosa (RP). The first, RP2 (type 2), was recently identified by positional cloning in Xp11.3. 4 A second locus, RP3 (type 3), is distal to RP2 between the DXS1110 and OTC loci in Xp21.1. 5, 6 RP3 is the disease locus in the majority of XLRP families. [7] [8] [9] Deletion analysis and a positional sequencing approach led to the identification of the RPGR (retinitis pigmentosa GTPase regulator) gene at the RP3 locus. 10 The predicted protein contains in its amino-terminal half a tandem repeat structure highly similar to RCC1 (regulator of chromosome condensation) suggesting an interaction with a small GTPase. 10 Mutations within conserved domains provide evidence that RPGR is the RP3 gene, but its function and the etiology of retinal degeneration are unknown.
The RPGR gene was shown to be mutated in only 10-15% of northern European RP3 families 10, 11 and in 20% of United States XLRP families. 12 Most mutations fall in exons encoding RCC1 repeats, the characteristic domain of the amino-terminal region of RPGR putative protein. It is conceivable that RPGR is not responsible for most cases of XLRP linked to this region and that another RP novel gene(s) remains unidentified. Another possibility is that identification of RPGR mutations escape detection because they are located in regulatory regions (eg promoter regions) or in additional coding sequences. 10, 13 To date 29 different RPGR mutations have been identified. [10] [11] [12] [13] [14] [15] Most mutations identified in European families have been different from those identified in the United States. To extend the information about the range, type, and frequency of RPGR mutations in different populations, the goal of the present study was to investigate southern European patients with XLRP. We report here the examination of all 19 exons of the RPGR gene in 34 XLRP families from Spain and 15 XLRP from Italy.
Materials and Methods

XLRP Patients
Patients were considered as XLRP on the basis of ocular examination, electroretinography (ERG) and assessment of visual field. 16, 17 Pedigrees showed no male-to-male transmission of the disease, and females were only mildly affected, consistent with X-linked inheritance. Clinical phenotypes of families XLRP-24 and XLRP-534 have been reported elsewhere. 13 In six families, the disease state was linked to the RP3 locus; in the others, linkage analysis was not possible.
Multiplex SSCA Screening
Genomic DNA for amplification reactions was extracted from the blood of affected individuals and other family members by standard procedure. 18 All individuals were informed about the objectives of the study and volunteered to participate. DNA samples were screened for mutations within the RPGR gene, by multiplex PCR/SSCA analysis. 19 The screen was performed for all 19 exons of the RPGR gene, using oligonucleotide primers described elsewhere. 10 Genomic DNA samples (200 ng) were co-amplified for three pairs of RPGR primers in a 12 µl reaction containing 7.5 mM MgCl 2 , 7.5 mM Tris-HCl (pH 8), 7.5m M Hepes, 50 mM KCl, 2 mM DTT, 0.01% gelatin, 2.5% formamide, 6.25 mM dNTPs, 0.5 mM each primer and 0.5 units Taq polymerase (Perkin Elmer, Foster City, CA, USA). After an initial denaturation step at 94°C for 5 min, PCR was performed for 30 cycles; each cycle consisted of 30 s of denaturation at 94°C, 45 s of annealing at an appropriate temperature, and 45 s at 72°C for extension; 4 µl of stop solution (95% formamide, 60 mM NaOH, 10 mM EDTA, 0.1% xylene cyanol and 0.1% bromophenol blue) were added to 3 µl of each sample. Amplification products were denatured for 4 min at 95°C, chilled in ice for 5 min and loaded on to SSCA gels. Gel formulations include 9% acrylamide/bis (60:1), 8% glycerol and 8% acrylamide/bis (50:1), 6% glycerol. Gels were run for 6-12 h at 4°C, 1200 V, and stained using a silver nitrate protocol. 20 
Reverse Transcriptase-PCR Analysis
Total RNA was isolated by the guanidine isothiocyanatephenol method 21 from Epstein-Barr virus-immortalised lymphocytes of probands of families XLRP-401, XLRP-DA, and XLRP-192. The cDNA was synthesised using random hexamers as primers and Superscript II RNase H Reverse (Life Technologies, Milan, Italy) according to the manufacturer's instructions. Subsequent amplification was done with primers: RT2 (5'-GTT TAA AAA TGA TGT CCC TGT A-3') and RT3 (5'-TTG ACA CAT GTT GGC TTG CTG A-3') for the splice site mutation in XLRP-401 (annealing 60°C); RT7 (5'-GTT AGG TCT TCC CAA TCA GC-3') and RT9 (5'-TTA GAG CAC AAA GTA GGA ATG AAG-3') for the splice site mutation in XLRP-DA (annealing 60°C); RT13 (5'-TTA AAA TTA TCA CCA GTT CA-3') and RT15 (5'-TTG CTC CTC TAT TCC ATT TC-3') for the splice site mutation in XLRP-192 (annealing 54°C). The PCR conditions consisted of an initial denaturation at 94°C for 5 min, followed by 35 cycles of denaturing at 94°C for 30 s, annealing at an appropriate temperature for min and extension at 72°C for 2 min, then a final extension at 72°C for 10 min with the same reagents described above.
Sequencing of PCR Products
In order to define mutations/sequence changes, DNA fragments that exhibited mobility shifts on SSCP analysis, as well as normal fragments and RT-PCR products for splice site mutations, were reamplified, gel purified using a Geneclean (Bio 101 Inc., Vista, CA, USA) gel extraction kit, and used as Novel mutations in RPGR gene t templates in a direct dideoxynucleotide chain termination reaction using dye terminator chemistry (Perkin Elmer) according to the manufacture's protocol. The primers employed for PCR reactions were used for sequencing and the products were analysed on an ABI PRISM 377 DNA sequencer (Perkin Elmer). All mutations were confirmed by sequence analysis in both directions in the affected individuals of each pedigree.
Results
In the cohort of 49 apparently unrelated XLRP families (34 Spanish and 15 Italian), seven novel mutations were identified in hemizygous affected males and heterozygous carrier females from eight XLRP families by multiplex-SSCP and direct automated sequencing. All seven mutations segregated with the disease in appropriate family members that were available for the study. Table 1 summarises the mutations observed in this study.
Missense Mutations
Two missense mutations (see Table 1 ) in the RCC1 domain were found in two families, one Spanish (XLRP-G9; Figure 1c Figure 2b ). Both amino acidic substitutions are within residues which are conserved across evolution. 10 These mutations were present in carrier females, affected males, absent in healthy males of each family and also in 120 control chromosomes suggesting that these are causative of the disease.
Microdeletions
Two different microdeletions were identified among the affected members of three unrelated families. One deletion (∆T545), which is a single thymine deletion at base 545 in exon 6, was found in affected males of Spanish family XLRP-G4 (Figure 1f) , causing a frameshift and premature termination signal in codon 174. This mutation has also been reported in another Spanish family XLRP-24, 13 but the two families are unrelated -at least in available pedigrees -and came from different parts of Spain. The second (∆AT296-297) was a deletion of two bases pairs at 296-297 in exon 3, causing a frameshift and premature termination signal in codon 86. This mutation has been identified in an Italian family XLRP-534 described previously. 13 
Splice-site Mutations
In three patients, splice site mutations were detected that cosegregated with the disease. The first (IVS2-2) was observed in an Italian family (XLRP-401; Figure 1b) . It is an A-> G transition (Figure 3a) at position -2, at the first intronic nucleotide of the splice-acceptor site of exon 3 (sequence designation is according to Meindl et al 10 ). To determine the effect of this mutation, we sequenced the RT-PCR products, spanning exons 2 and 3, from the proband lymphocyte RNA. Our results show that the mutant transcript of 606 bp includes intron 2, resulting in a failure to recognise the affected intron (Figure 3a) . Intron 2 is therefore retained in the final mRNA product. As a result, a new stop codon is encountered within the first three nucleotides of the intron, resulting in a severely truncated polypeptide of ). All mutations were tested in 120 control chromosomes; a described in Miano et al; 13 b Family linked to RP3 locus.
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193 residues lacking the RCC1 domains. The sequence alteration generated a new HpaII restriction site and the loss of a BstNI restriction site, which segregate with the disease in the family (data not shown). The second splice site mutation (IVS8 + 1) is a G-> A transition (Figure 3b ) at position + 1 in the splice-donor region of exon 8, observed in another Italian family, XLRP-DA (Figure 1e ). Sequence analysis of RT-PCR products from lymphocyte RNA from the proband was performed with primers that span exons 7 to 9. The sequence change results in the skipping of exon 8 (156 nt), and leads to an in-frame deletion of an RCC1 repeat (Figure 3b) .
The third splice site mutation (IVS13-2) was observed in a Spanish family, XLRP-192 (Figure 1a) . It is also an A-> G transition (Figure 3c ) at position -2 in the splice-acceptor site of exon 14. Sequence analysis of RT-PCR products from lymphocyte RNA from the proband was carried out with primers spanning exons 13 to 15. Similar to mutation IVS8 + 1, this sequence alteration results the skipping of an exon (exon 14, 185 bp), and leads to an in-frame deletion in the carboxy-terminal region of the RPGR protein (Figure 3c ). This consequence is a protein with a small 'charged domain'. 12 These three mutations were absent in 70 XLRP and 120 control chromosomes, indicating that they are not simply frequent variant alleles in these populations.
Sequence Variations
Several base substitutions (exonic and intronic) were detected by multiplex-SCCA and specified precisely by sequence analysis, in both patients and control samples Table 1 ). Symbols used are described at the bottom of the figure Novel mutations in RPGR gene t (see Table 2 ). We identified seven new sequence variants in some of 120 control chromosomes and 22 XLRP patients. They include two silent mutations in exon 2 (S47S), exon 7 (K244K) and one conservative substitution in exon 14 (T533M) and four intronic variants in intron 10 (IVS10 + 16), intron 12 (IVS12-101; IVS12-130), intron 17 (IVS17 + 46). Additional sequence variants detected during our studies have been described elsewhere. They include two silent mutations in exon 11 (R425K; I431V), in unaffected individuals, producing conservative amino acid substitutions. 11, 12 We also identified one silent mutation in exon 10 (A388A), one conservative substitution in exon 14 (G566E), and three intronic variants in intron 1 (IVS1-15), intron 13 (IVS13 + 11), intron 18 (IVS18 + 11), all previously described by Buraczynska. 12 Any affect of these changes on splicing has not been determined.
Discussion
Long-range sequencing in X-linked retinitis pigmentosa led to the discovery of mutations in the RPGR gene. 10 Expression of RPGR has been demonstrated in all neuronal layers of the retina and in RPE. The protein is seen both in cytoplasm and nucleoplasm, particularly in the vicinity of nuclear pores, in membranous organelles surrounding the nucleus and the inner and outer segments of both rod and cone photoreceptors. 22, 23 But all studies indicate that RPGR is expressed at surprisingly low levels in the retina, and it is unclear how mutations in this gene cause retinal degeneration.
Mutations in RPGR (see Figure 4 ) have been identified in only 10-15% of northern European RP3 families 10, 11 and in 20% of United States XLRP families. 12 The low percentage of XLRP families with RPGR mutations is consistent with recent reports indicating that RPGR mutations were found in XLRP families less frequently than the 60-90% level originally predicted by linkage analysis of XLRP pedigrees. [7] [8] [9] 12 Thus, other genes might be quantitatively more important as causes of XLRP. On the other hand, it remains a possible alternative that because the sensitivity of mutation-detection methods is not adequate, mutations may have escaped detection, possibly because they occur in regulatory regions (eg promoter region) or in additional coding sequences. 10, 13 Studies of different populations might reveal a range of mutations that would help to distinguish between these alternatives. Here, among 49 southern European XLRP families, eight carried seven different RPGR mutations in coding regions and splice sites. None of the 29 RPGR mutations already reported in other populations were seen. This result demonstrates the diversity of RPGR mutations responsible for XLRP in different populations. It is consistent with the inference that most RP3 mutations are of independent origin. 24 Different clinical presentations have been recognised in XLRP, 3 and some genotype-phenotype correlations have been attempted in hemizygous males and heterozygous carrier female in XLRP families. [25] [26] [27] 15 The location and nature of RPGR mutations might help to understand the molecular basis of XLRP and the role of the RPGR protein in photoreceptor function. Six of 12 The amino-terminal half of the predicted RPGR protein contains 6-7 repeats with similarity to repeats within RCC1, a protein which is essential for nucleocytoplasmic transport, though it might also be involved in protein trafficking through the Golgi apparatus. 28 Most RPGR mutations fall in the RCC1 repeats, providing evidence that it is an important functional domain. Recently, studies to identify proteins that interact with RPGR, showed that the RCC1-like domain of RPGR interacts with phosphodiesterase delta subunit. 29 This interaction links RPGR to the visual transduction cascade that regulates the rod phosphodiesterase holoenzyme, 30 though no specific related activity (eg of guanine nucleotide exchange) has been identified. The large group of XLRP families in which no mutations have been detected in RPGR provide one starting point for the study of interacting proteins or additional mutations that regulate RPGR. Novel mutations in RPGR gene t
